%0 Journal Article %T RAS Mutation in Mucinous Carcinoma of the Ovary %J Asian Pacific Journal of Cancer Prevention %I West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. %Z 1513-7368 %A Panyavaranant, Pinyada %A Teerapakpinyo, Chinachote %A Pohthipornthawat, Natkrita %A Oranratanaphan, Shina %A Shuangshoti, Shanop %A Triratanachat, Surang %D 2019 %\ 04/01/2019 %V 20 %N 4 %P 1127-1132 %! RAS Mutation in Mucinous Carcinoma of the Ovary %K genetic mutation %K mucinous %K Ovarian Cancer %K KRAS %K survival %R 10.31557/APJCP.2019.20.4.1127 %X Objective: This study was designed to identify genetic mutation in mucinous carcinoma of the ovary of the patientsin King Chulalongkorn Memorial hospital, Bangkok, Thailand and study the relationship between genetic mutationand patients’ prognosis. Methods: Fifty cases of primary mucinous carcinoma of the ovary were selected. DNA wasanalyzed for genetic mutation using ColoCarta Panel v1.0 and MassArray® System. Demographic data and clinicalinformation of the participants were reviewed from electronic medical records and government data services. Results:Median of disease-free survival is 171.33 +/- 9.04 months and the median overall survival is 171.37 +/- 9.03 months.Twelve percent of the participants had recurrence and all of recurrent cases died from disease or its complication. Wefound three mutations which were KRAS (27 cases, 54%), PIK3CA (4 cases, 8%) and BRAF (1 case, 2%). Among theKRAS-mutated patients, the majority of the cases (25 cases, 92.6%) were in stage I. Recurrence and disease relatedmortality were not observed in the KRAS mutated patients. Conclusion: The genetic mutation analysis found threemutations which were KRAS 27 cases (54%), PIK3CA 4 cases (8%) and BRAF 1 case (2%) The ovarian mucinouscarcinoma patients with KRAS mutation in our study showed excellent prognosis. %U https://journal.waocp.org/article_85943_5a430e711a8f9464db901a2519296e6b.pdf